• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Canada-Based Niagara Pharmaceuticals Plans Cowpens, South Carolina, Operations

Niagara Pharmaceuticals, a manufacturer of eye health and safety products, will establish its first United States operation in Cowpens, South Carolina. The $9 million project is expected to create 45 jobs in Cherokee County.

Located at 1290 Mt. Olive Road, the facility will accommodate additional production capacity to meet increasing demand for the company’s products. Operations are planned for 2023.

“Niagara Pharmaceuticals is excited to launch our first U.S. operation in Cherokee County. In addition to South Carolina’s business-friendly environment and talented workforce, the state’s strategic location will allow us to connect more efficiently with our customers in the region. We look forward to growing our company and being a part of the South Carolina community,” Niagara Pharmaceuticals CEO Andrew Leistner said.

As an incentive, the Coordinating Council for Economic Development approved job development credits related to this project and awarded a $200,000 Rural Infrastructure Fund grant to Cherokee County to assist with the costs of building improvements.

“We’re excited to celebrate another South Carolina win today with the announcement of Niagara Pharmaceuticals’ new operation in Cherokee County. When an international company decides to locate in South Carolina, particularly in one of our rural communities, it shows the world that we have the business environment to attract companies to all corners of our state. Congratulations to Niagara Pharmaceuticals. We proudly welcome them to our state’s life sciences manufacturing community,” Secretary of Commerce Harry M. Lightsey III added.

Niagara Pharmaceuticals offers multiple eye products including contact lens cleaner, emergency wash, and self-contained eyewash station additive through brands Health Saver and Pur-Wash.

Exclusive Research